<?xml version="1.0" encoding="UTF-8"?>
<p>Moreover, 
 <italic>SwissADME</italic> tool showed that spirooxindole 
 <bold>6a</bold> fulfils the drug-likeness characteristics as defined by the major pharmaceutical companies (
 <xref rid="t0008" ref-type="table">Table 8</xref>) and passed their filters; Lipinski’s (Pfizer)
 <xref rid="CIT0041" ref-type="bibr">
  <sup>41</sup>
 </xref>, Veber’s (GSK)
 <xref rid="CIT0042" ref-type="bibr">
  <sup>42</sup>
 </xref> and Egan’s (Pharmacia)
 <xref rid="CIT0043" ref-type="bibr">
  <sup>43</sup>
 </xref> filters, whereas it failed to pass Ghose’s (Amgen) filter due to two violations; molecular weight &gt; 480, and molar refractivity &gt;130
 <xref rid="CIT0044" ref-type="bibr">
  <sup>44</sup>
 </xref>. However, it was not classified as lead-like because its molecular weight is higher than 350 and its predicted XLOGP3
 <xref rid="CIT0045" ref-type="bibr">
  <sup>45</sup>
 </xref> exceeded 3.5.
</p>
